Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Davey50, I don't have a problem with your posts, but it's important to remember that stocks don't always go up every single day. That's why I've shifted my focus from long-term to short-term investing. There's a lot of hype surrounding certain stocks, sometimes unethically so.
I learned the hard way from holding onto an AIM stock for too long. Now, I aim to take advantage of short-term price movements. There will be wins and losses, and that's simply part of the investing game.
Several OEMs are currently evaluating the ENET's UEP5
The global market for Carrier Ethernet Access devices was estimated to be valued at US$17.2 billion in 2022[1] and several OEMs are currently evaluating the Company's UEP. The UEP is available to potential customers either through licensing of the Company's IP or via sales of complete systems, including software applications up to an eASIC offering. While the majority of the ongoing discussions with OEMs for Ethernity's UEP are in the field of support for wireless link bonding, certain potential opportunities are targeting general purpose Carrier Ethernet Switch appliances, which include other unique monitoring and AI differentiated networking functions. Ethernity is able to provide a differentiated and cost-effective offering to its clients due to the Company's proprietary IP and technology.
Unified Ethernet Packet (UEP)
I just seen multiple large block buys 500k and 600k
Screen shot: https://prnt.sc/kO2zOmjs3Z6d
The bigger focus is the potential for substantial revenue growth for Mirriad. By scaling their operations through automation, they hope to attract more advertisers and sell more in-content placements.
let's see where this is going to be in next couple of days. ISA top-up done!
β
Mirriad Advertising Plc Announces Programmatic Partnership with TripleLift
What happened: Mirriad, the leader in in-content advertising and virtual product placement, has entered into a partnership with TripleLift, a major supply-side platform for advanced ad formats.
β
Key benefits of the partnership:
Automated ad buying: Advertisers and media buyers can now purchase Mirriad's in-content inventory through their preferred programmatic platforms like Google's DV360.
β
Increased efficiency and scalability: Programmatic buying makes the process of buying and selling in-content ads more efficient and allows Mirriad to scale their operations significantly.
β
Expansion into new markets: The partnership facilitates access to content from major entertainment conglomerates, diverse-owned creators, and across CTV, VOD, and FAST.
β
Why it matters: This partnership is an important step towards making in-content advertising a new standard in the digital advertising landscape. It addresses increasing demands from advertisers looking to reach wider audiences in the streaming age.
β
CEO Quote: Mirriad CEO, Stephan Beringer, emphasizes the partnership's game-changing potential, simplifying and automating the process for advertisers while expanding Mirriad's reach and revenue potential.
Here's a breakdown of the key information from the RUA Life Sciences Plc business update:
Overall Performance
Despite operational challenges in the first half of FY24, RUA Life Sciences is on track to meet expectations with revenue of Β£2.2 million.
β
Gross margins are expected to exceed expectations.
The company has maintained strict cost control resulting in operating costs of Β£3.4 million, below market expectations.
Strong financial position with a cash balance of approximately Β£4.0 million.
β
Business Development Successes
RUA has secured a major contract with a global company to significantly grow its contract manufacturing division, with an initial Β£100,000 purchase order.
The company's novel composite material for heart valves is achieving promising results in testing, demonstrating superior performance against current market offerings. RUA is actively pursuing partnerships in this sector.
Chairman's Comments
Bill Brown highlights that FY24 results represent progress towards the Group's strategy and that efforts to focus on growth are starting to yield positive outcomes.
He emphasises the major contract win as validation of RUA's expertise, bringing the company closer to profitability.
Bill expresses confidence in their potential to revolutionize heart valve technology with their unique material, actively seeking to form partnerships.
RUA Life Sciences group current Mcap under Β£5.5 million π
If RUA captures just 1% of the heart valve market = $200 million π
1% market share = $200 million
Those are the facts and investors should be aware that RUA hydrodynamic testing demonstrated valve efficiency around 50% better than current technology. πππ
and valve flow area is around 25% larger than similar sized valves in the market. ππ
We have a far superior product coming, and the two Edwards and Medtronic big players will be eager to get their hands on it.
Another 1 million added under 1p. What a bargain bucket compared to 3.45p paid by punters a couple of weeks ago.
Buy when everyone else is selling and hold until everyone else is buying. That's not just a catchy slogan. It's the very essence of successful investing.